Research Article: Pretreatment Neutrophil-to-Lymphocyte Ratio as Prognostic Biomarkers in Patients with Unresectable Hepatocellular Carcinoma Treated with Hepatic Arterial Infusion Chemotherapy Combined with Lenvatinib and Camrelizumab
Introduction:
Hepatocellular carcinoma (HCC) is the most prevalent primary liver cancer and the third major cause of cancer-related deaths worldwide; the World Health Organization estimates that the number of deaths caused by liver cancer will reach . million by . , While surgical resection remains an effective treatment for HCC, approximately % of patients with HCC are ineligible for radical treatment options, including surgical resection, once diagnosed due to late onset of symptoms, which is referred to as unresectable HCC…
Read more